麥迪衛康(02159.HK):中期股東應佔虧損爲612.3萬元
格隆匯8月28日丨麥迪衛康(02159.HK)發佈公告,截至2025年6月30日止六個月,實現收入人民幣1.27億元,同比減少9.7%;毛利爲人民幣2178.4萬元,同比增加5.3%;公司擁有人應佔虧損爲人民幣612.3萬元,上年同期公司擁有人應佔虧損爲人民幣2221.3萬元;基本每股虧損人民幣3.20分。
集團的整體毛利由截至2024年6月30日止六個月的約人民幣2070萬元增加約人民幣110萬元至報告期的約人民幣2180萬元。集團的整體毛利率由截至2024年6月30日止六個月的14.7%微升至報告期的17.1%,主要由於集團的業務戰略爲將重點放在利潤率較高的項目上所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.